Paul Mitchell

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · The Lancet Oncology · 2013 · 526 citations · Full text

Medicine, Oncology, Pharmacology +13

Differences in cancer survival by sex: a population-based study using cancer registry data

Nina Afshar, Dallas R. English, Vicky Thursfield et al. · Cancer Causes & Control · 2018 · 256 citations

Medicine, Biostatistics, Oncology +16

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

Anna K. Nowak, Michael Byrne, Raymond Williamson et al. · British Journal of Cancer · 2002 · 228 citations · Full text

Medicine, Oncology, Pharmacology +16

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies

Hongdo Do, Michael Krypuy, Paul Mitchell et al. · BMC Cancer · 2008 · 207 citations · Full text

Medicine, Oncology, Pathology +17

Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting

C. Chouaïd, Jason Agulnik, Erdem Göker et al. · Journal of Thoracic Oncology · 2013 · 144 citations · Full text

Pharmacy, Oncology, Health Assessment +16